GlassScriptPhysician profile
Babak Tashakkor
NPI 1548227796
$28,133.16
in general payments reported to CMS, 2019-2025
39 companies · $2,473 in 2025
The $2,473 reported for 2025 was more than what 86% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,048 · 2020: $1,620 · 2021: $1,900 · 2022: $6,772 · 2023: $4,995 · 2024: $3,324 · 2025: $2,473.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,677 · Travel and Lodging: $1,890 · Consulting Fee: $1,225.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,677.36 |
| Travel and Lodging | $1,889.98 |
| Consulting Fee | $1,225.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $9,104.11 | 2019-2025 | Gallant, Aveir, Merlin@Home |
| Biotronik INC. | $7,057.61 | 2019-2024 | Rivacor 7 Dr-T, Edora 8 Dr-T |
| Novartis Pharmaceuticals Corporation | $1,641.30 | 2019-2025 | |
| Pfizer INC. | $1,509.62 | 2019-2025 | |
| Amgen INC. | $1,254.65 | 2019-2025 | Repatha, Repatha |
| Edwards Lifesciences Corporation | $689.96 | 2019-2025 | Konect Resilia, Evoque, Sapien 3 Ultra Resilia |
| Merck Sharp & Dohme LLC | $661.18 | 2021-2025 | Verquvo, Capvaxive |
| Boston Scientific Corporation | $650.13 | 2019-2025 | Accolade Sr, Watchman Flx, Emblem Mri S-Icd |
| E.R. Squibb & Sons, L.L.C. | $580.81 | 2019-2024 | Camzyos, Eliquis |
| Astrazeneca Pharmaceuticals LP | $572.98 | 2021-2025 | Wainua, Farxiga |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $414.47 | 2019-2025 | Lifevest |
| Esperion Therapeutics, INC. | $411.66 | 2020-2025 | Nexletol |
| Janssen Pharmaceuticals, INC | $378.57 | 2019-2024 | Xarelto |
| Medtronic, INC. | $357.85 | 2024-2025 | Micra, Azure Xt Dr Mri Surescan, Linq II |
| Boehringer Ingelheim Pharmaceuticals, INC. | $349.79 | 2019-2025 | Jardiance |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Babak Tashakkor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.